Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study.
Mette Thune MouritzenKaren F JunkerAndreas CarusMorten LadekarlPeter MeldgaardAnders Winther Mølby NielsenAnna LivbjergJacob W LarsenHalla SkuladottirCharlotte KristiansenKim WedervangTine SchytteKarin H HansenAnne-Cathrine ØstbyMalene S FrankJakob LauritsenJens Benn SørensenSeppo Wang LangerGitte F PerssonJon L AndersenPernille H HomannEmilie B KristensenLars B DrivsholmMartin BøgstedHeidi S ChristensenMette PøhlBirgitte BjørnhartPublished in: Acta oncologica (Stockholm, Sweden) (2022)
Danish real-world patients with advanced NSCLC treated with second- or subsequent-line ICI had an OS comparable to results from RCTs. Women, frail and older patients constituted a higher proportion than in previous RCTs. Clinical features associated with poor OS were male sex, PS ≥1 (in particular PS ≥2), bone-, and liver metastases.